Show notes
Featuring perspectives from Dr Emmanuel Antonarakis, Prof Karim Fizazi, Dr Maha Hussain and Dr Matthew Smith, moderated by Dr Alan Bryce, including the following topics:
• Management Approaches for Nonmetastatic Prostate Cancer — Dr Bryce
o Introduction (00:00)
o Case: A man in his early 70s with Gleason 8 prostate cancer after EBRT and leuprolide/enzalutamide, now receiving leuprolide/darolutamide with focal prostate uptake on PSMA PET — Priya Rudolph, MD, PhD (3:04)
o Case: A man in his late 60s who underwent prostatectomy for Gleason 4 + 3 = 7 prostate cancer, now with increasing PSA levels — Nataliya Mar, MD (8:35)
o Faculty presentation: Dr Bryce (15:12)
• Optimizing the Care of Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — Dr Hussain
o Cases: A man in his early 70s with de novo mHSPC and a man in his mid 90s with de novo mHSPC — Georges Azzi, MD and Swati Vishwanathan, MD (23:29)
o Case: A man in his early 70s with atrial fibrillation and rapid ventricular response who is diagnosed with de novo mHSPC (PSA 180,000 ng/mL) — Eric H Lee, MD, PhD (32:37)
o Faculty presentation: Dr Hussain (37:34)
• Current Therapeutic Options for Patients with Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Smith
o Case: A man in his early 60s with de novo metastatic prostate cancer — Lai (Amber) Xu, MD, PhD (48:49)
o Case: A man in his late 70s with mCRPC — Dr Rudolph (53:36)
o Faculty presentation: Dr Smith (58:37)
• Best Practice Management of mCRPC for Patients Harboring HRR Gene Alterations — Dr Antonarakis
o Case: A man in his mid 70s with mCRPC with an ATM mutation who receives olaparib — Dr Vishwanathan (1:06:38)
o Case: A man in his mid 70s with de novo mCRPC with a BRCA2 mutation who received multiple treatments and is now responding to olaparib but with transfusion-dependent neutropenia — Sunil Gandhi, MD (1:17:00)
o Faculty presentation: Dr Antonarakis (1:21:30)
• Current and Emerging Strategies for Patients with Recurrent mCRPC — Prof Fizazi
o Case: A robust man in his mid 80s with mCRPC and rapid, symptomatic progressive disease through multiple treatments, now with extensive liver and bone metastases and small cell transformation — Vignesh Narayanan, MD (1:32:58)
o Case: A man in his mid 70s with BRCA wild-type mHSPC who enrolls on a clinical trial of ADT/enzalutamide with or without a PD-1 inhibitor — David S Morris, MD (1:37:50)
o Faculty presentation: Prof Fizazi (1:45:18)
CME information and select publications
Our TOPPODCAST Picks 
Stay Connected
